A Hypertensive Reaction Induced by Concurrent Use of Selegiline and Dopamine

Abstract

Spanish

French

OBJECTIVE:

To describe a hypertensive reaction induced by concurrent use of selegiline and dopamine.

CASE SUMMARY:

A 75-year-old critically ill white man who was receiving selegiline 5 mg twice daily for Parkinson's disease was initiated on an intravenous dopamine infusion for decreased urine output and hypotension. Within minutes of starting the dopamine infusion, the patient's systolic blood pressure increased from 105 to 228 mm Hg. Similar reactions occurred during two subsequent rechallenges.

DISCUSSION:

Since monoamine oxidase is involved in the metabolism of catecholamines, selegiline may have affected the metabolism of the dopamine administered to the patient. Although selegiline is known to be a monoamine oxidase inhibitor specific for type B, evidence exists stating that selegiline may not be as specific as previously thought.

CONCLUSIONS:

Dopamine should be used cautiously, if at all, in patients who are chronically receiving selegiline or who have received selegiline within the prior two weeks.

Keywords

selegiline dopamine monoamine oxidase inhibitors

Get full access to this article

View all access options for this article.

References

Knoll

. Critical role of MAO inhibition in Parkinson's disease. Adv Neurol 1996;45:107–10.

Koller

Giron

. Selegiline HCl: Selective MAO -type B inhibitor. Neurol 1990;40(suppl 3):58–60.

Dasta

Kirby

. Pharmacology and therapeutic use of low-dose dopamine. Pharmacother 1989;6:304–10.

Baldessarini

. Drugs and the treatment of psychiatric disorders: Depression and mania. In: Hardman

Limbird

Molinoff

Ruddon

Gilman

, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:431–59.

Schulz

Antonin

Hoffmann

Jedrychowski

Nilsson

Schick

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Phamacol Ther 1989;46: 528–36.

Sunderland

Mueller

Cohen

Jimerson

Pickar

Murphy

. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacol 1985;86:432–7.

Naranjo

Busto

Sellers

Sandor

Ruiz

Roberts

A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.

Brown

Powell

Craig

. Immunological studies on human monoamine oxidase. J Neurochem 1982;32:1266–70.

Jarrott

Vajda

FJE

. The current status of monoamine oxidase and its inhibitors. Med J Aust 1987;146:634–8.

10.

Lan

Chen

Shih

. Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells. J Neurochem 1989;52: 1652–4.

11.

O'Carroll

Anderson

Tobbia

Phillips

J P

Tipton

. Determination of the absolute concentrations of monoamine oxidase A and B in human tissues. Biochem Pharmacol 1989;68:901–5.

12.

Oreland

. Monoamine oxidase, dopamine, and Parkinson's disease. Acta Neurol Scand 1991;84(suppl 136):60–5.

13.

Reiderer

Konradi

Schay

Kienzl

Birkmayer

Danielczyk

Localization of MAO-A and MAO-B in human brain: A step in understanding the therapeutic action of L-deprenyl. Adv Neurol 1986;45: 111–8.

14.

Gerlach

Youdim

MBH

Riederer

. Pharmacology of selegiline. Neurology 1996;47(suppl 3):S137–45.

15.

Youdim

MBH

Finberg

JPM

. Pharmacological actions of L-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors. Clin Pharmacol Ther 1994;56:725–33.

16.

Waldmeier

Felner

. Deprenil: Loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem Pharmacol 1978;27: 801–2.

17.

Gerlach

Riederer

Youdim

MBH

. The molecular pharmacology of L-deprenyl. 1992;226:97–108.

18.

Prasad

Glover

Goodwin

Sandler

Signy

Smith

. Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment. Psychopharmacol 1988;95:540–3.

19.

McGrath

Stewart

Quitkin

. A possible L-deprenyl—induced hypertensive reaction. J Clin Psychopharmacol 1989;9:310–1.

20.

Robinson

. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Biochem Pharmacol 1985;34:4105–8.

21.

Hoffman

Lefkowitz

Taylor

. Neurotransmission: The autonomic and somatic motor nervous systems. In: Hardman

Limbird

Molinoff

Ruddon

Gilman

, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw Hill, 1996:105–40.

22.

Teychenne

Calne

Lewis

Findley

. Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic acid decarboxylase. Clin Pharmacol Ther 1975;18:273–7.

23.

Horwitz

Goldberg

Sjoerdsma

. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J Lab Clin Med 1960;56:747–53.